Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia
Chakrapani Tripathi, Frank Luh, Yun Yen · 2026
Read Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia by Chakrapani Tripathi, Frank Luh, Yun Yen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13186020.txt.
Description
Chakrapani Tripathi, Frank Luh, and Yun Yen report a safer way to aim engineered T cells at acute myeloid leukemia, in a 2026 paper. Their recent work builds receptors from llama single-domain antibodies, called nanobodies, set on the CLL-1 marker found on leukemia cells. A twin build aimed at a second marker, CD33, served as the contrast. Lab and mouse tests scored killing power, T cell firing, and harm to healthy blood stem cells.
The CLL-1 cells killed leukemia hard, fired cleanly, and spared healthy stem cells, which kept their power to form colonies and blood lines. In mice, the therapy cleared tumors for good with little side harm. The CD33 build lacked that safety edge.
Catalog record
| CREATOR | Chakrapani Tripathi, Frank Luh, Yun Yen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 8 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |